Literature DB >> 16286804

Multifocal electroretinography changes in the macula at high altitude: a report of three cases.

Mitrofanis Pavlidis1, Tobias Stupp, Ilias Georgalas, Evi Georgiadou, Michail Moschos, Solon Thanos.   

Abstract

BACKGROUND: To evaluate the short- and long-term effects of high-altitude hypobaric hypoxia on macula morphology and function during ascents, acclimatizations, and descents between 500 m and 5,650 m, macula function was evaluated in three healthy climbers of a trekking expedition.
METHODS: Macula physiology was tested with multifocal electroretinography (MF ERG), near and farvisual acuity, and Amsler grid tests. Macula morphology was tested with optical coherence tomography (OCT) and with stereoscopic fundoscopy obtained 1 week before ascent, as well as 1 week and 2 weeks after high-altitude exposure. The following physiological parameters indicative of acclimatization were compared daily during the expedition at altitudes between 500 m and 5,050 m: hemoglobin, oxygen saturation, resting heart rate, retinal findings, and the Lake Louise score of acclimatization.
RESULTS: The central macula MF ERG responses were significantly reduced 1 week after high-altitude exposure, and had recovered by the follow-up examination performed during the following week. Near visual acuity and Amsler grid tests remained unaffected at both follow-up examinations. No significant changes were found in the follow-up OCT and daily fundoscopy examinations in all three well-acclimatized climbers.
CONCLUSIONS: High-altitude hypobaric hypoxia affects the function of the highly sensitive macula region. This suggests that the exposure of persons with macula diseases such as age-related macula degeneration, tapetoretinal degeneration, or diabetic retinopathy to high altitudes may influence the disease progression. For this reason, this population should avoid prolonged and unnecessary high-altitude exposure without proper acclimatization. Copyright 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2005        PMID: 16286804     DOI: 10.1159/000088387

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  3 in total

1.  Systemic oxygen therapy versus oral enalapril for treatment of diabetic macular ischemia: a randomized controlled trial.

Authors:  Farideh Sharifipour; Mohammadreza Razzaghi; Alireza Ramezani; Mohsen Azarmina; Mehdi Yaseri; Roham Soheilian; Masoud Soheilian
Journal:  Int Ophthalmol       Date:  2015-08-21       Impact factor: 2.031

2.  Structural and functional changes of the human macula during acute exposure to high altitude.

Authors:  M Dominik Fischer; Gabriel Willmann; Andreas Schatz; Kai Schommer; Ahmad Zhour; Eberhart Zrenner; Karl U Bartz-Schmidt; Florian Gekeler
Journal:  PLoS One       Date:  2012-04-30       Impact factor: 3.240

3.  Low-level night-time light therapy for age-related macular degeneration (ALight): study protocol for a randomized controlled trial.

Authors:  Claire McKeague; Tom H Margrain; Clare Bailey; Alison M Binns
Journal:  Trials       Date:  2014-06-24       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.